ctDNA Test Guides Breast Care in Elderly
Blood-based monitoring may help tailor less invasive treatment decisions
Clinical Scorecard: ctDNA Test Guides Breast Care in Elderly
At a Glance
| Category | Detail |
|---|
| Condition | Estrogen receptor-positive breast cancer in elderly women |
| Key Mechanisms | ctDNA as a biomarker for tumor dynamics and treatment response |
| Target Population | Women aged 70 years and older with breast cancer |
| Care Setting | Community-based care |
Key Highlights
- ctDNA testing can identify patients who may avoid surgery and rely on endocrine therapy.
- Persistent ctDNA after 6 months indicates tumor progression risk.
- Negative ctDNA at baseline correlates with no disease progression.
- ctDNA testing allows for decentralized and frequent monitoring.
- Pretreatment ctDNA positivity is linked to higher progression risk.
Guideline-Based Recommendations
Diagnosis
- Use ctDNA testing to assess tumor dynamics and treatment response.
Management
- Consider endocrine therapy for ctDNA-negative patients to avoid surgery.
Monitoring & Follow-up
- Implement routine ctDNA testing for ongoing disease monitoring.
Risks
- Avoid escalation to surgery or radiation in ctDNA-negative patients due to morbidity.
Patient & Prescribing Data
Elderly women with estrogen receptor-positive breast cancer
ctDNA can guide treatment decisions and monitor disease progression.
Clinical Best Practices
- Integrate ctDNA testing into routine care for personalized treatment pathways.
- Utilize ctDNA as a complementary tool alongside traditional pathology markers.
References
